Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon May 23, 2013 2:03pm
173 Views
Post# 21432848

RE: RE: RE: RE: RE: Effective date

RE: RE: RE: RE: RE: Effective date

You are right! My apologies for my previous mistake. Here is the excerpt from the arrangment circular about the use of the Due Bill procedure:

"The TSX has determined that the Due Bill trading procedure will be used in connection with the distribution of the Newco Shares to Resverlogix Shareholders pursuant to the Arrangement. As a result of the use of Due Bills, any Resverlogix Shareholder who purchases their Resverlogix Shares on the TSX in the period two days prior to the Distribution Record Date up to and including the payment date of the Newco Shares issuable pursuant to the Arrangement will be entitled to receive the Newco Shares. Any trades that are executed during this period will be automatically flagged to ensure that such purchasers receive the entitlement to the Newco Shares and the sellers do not. See “Procedure for the Receipt of Newco Shares - Information Concerning Due Bills”

Bullboard Posts